High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma
作者单位：Research Center of Clinical MedicineAffiliated Hospital of Nantong University Department of Biochemistry and Molecular BiologySchool of Basic Medical SciencesFudan University Department of UrologyFudan University Shanghai Cancer Center
会议名称：《2017年中国肿瘤标志物学术大会暨第十一届肿瘤标志物青...》
会议日期：2017年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
关 键 词：mucin 5AC clear cell renal cell carcinoma overall survival recurrence-free survival prognostic biomarker
摘 要：Background: Mucin 5 AC（MUC5 AC）, as a member of secreted/gel-forming mucin family, was frequently found to be abnormally expressed in inflammation or malignant diseases. However, the clinic pathologic features and prognostic values of MUC5 AC in clear cell renal cell carcinoma（ccRCC） have not been reported up to now. Methods: MUC5 AC expression was analyzed by immunohistochemistry on tissue microarrays. KaplanMeier survival curves, Univariate and Multivariate Cox analysis and newly-established nomogram model were performed to evaluate the prognostic value. Results: MUC5 AC expression was firstly found to be up-regulated in patients with ccRCC, positively associated with tumor size, pN stage, lymphovascular invasion, Fuhrman grade, rahbdoid differentiation, sarcomatoid features, tumor necrosis, ECOG-PS and recurrence. Furthermore, MUC5 AC expression might be contributed to risk stratification of ccRCC patients with TNM stage Ⅲ+Ⅳ or Fuhrman grade 3 or 4 for overall survival（OS） and recurrence-free survival（RFS） analysis, and it was demonstrated to be negatively correlated with OS and RFS of ccRCC patients. What’s more, MUC5 AC was identified as a potential independent adverse prognostic factor;prediction accuracy of MUC5 AC-based new nomogram model was drastically improved for OS and RFS of ccRCC patients. Conclusion: MUC5 AC is a promising independent adverse prognostic factor for ccRCC patients, it maybe conducive to postoperative risk stratification and guide treatment in the future.